Comparative Pharmacology
Head-to-head clinical analysis: PARLODEL versus ROPINIROLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARLODEL versus ROPINIROLE HYDROCHLORIDE.
PARLODEL vs ROPINIROLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
Ropinirole is a non-ergoline dopamine agonist with high affinity for D2 and D3 dopamine receptors, particularly D3. It stimulates postsynaptic dopamine receptors in the striatum, compensating for dopamine deficiency in Parkinson's disease and modulating dopaminergic pathways in restless legs syndrome.
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
Initial: 0.25 mg orally three times daily; titrate weekly by increments of 0.25 mg three times daily up to 1 mg three times daily, then 0.5 mg three times daily up to 3 mg three times daily; maximum 8 mg three times daily (24 mg/day).
None Documented
None Documented
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Terminal elimination half-life: 5-6 hours in young healthy adults; 6-8 hours in elderly. Clinically, steady-state achieved within 2 days.
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Renal: 88% (primarily as metabolites, <10% unchanged). Fecal: <5%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist